Soluble fms-like tyrosine kinase-1 and atherosclerosis in chronic kidney disease.
Vascular endothelial growth factor (VEGF) and its cousins, such as placental growth factor, have moved into the daily clinical arena. One-step-removed regulators, such as the VEGF splice variant soluble fms-like tyrosine kinase-1 (sFlt-1), now clinically emerge. sFlt-1 keeps our corneas 'clean.' However, sFlt-1 could also cause disease, such as preeclampsia. The report by Matsui et al. on ApoE and sFlt-1 gene-deleted mice could foster important subsequent research. We are limited only by our imaginations.
1] Experimental and Clinical Research Center, Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine, Berlin, Germany [2] Department of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Friedrich C
FC
Luft
D000818:Animals; D050197:Atherosclerosis / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D051436:Renal Insufficiency, Chronic / Q000150:complications*; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000097:blood*
C501162:FLT1 protein, human; C501163:Flt1 protein, mouse; D040281:Vascular Endothelial Growth Factor Receptor-1